Skip to Main Content

Casma Therapeutics, a Cambridge biotech trying to develop new medicines based on discoveries about how cells detoxify and repair themselves, has raised $50 million in fresh venture capital and wants to use the money to create drugs for treating muscular dystrophy.

It’s the second fund-raising round for Casma, which was launched by Boston-based Third Rock Ventures in 2018 with $58 million in venture capital. The latest fund-raising effort was led by The Column Group, of Pacifica, Calif., and added several new investors, including Eventide Asset Management of Boston and Swiss-based Schroder Adveq.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!